CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
921.29MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6320xvs all stocks
52-Week Change
110.52%vs all stocks
Market Capitalization
921.29MUSDvs all stocks (USD)
Enterprise Value
753.46MUSDvs all stocks (USD)
Forward P/E
-7.00xvs Biotechnology peers
Price to Book (MRQ)
3.23xvs Biotechnology peers
Enterprise to EBITDA
-4.51xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-44.38%vs Biotechnology peers
Return on Equity (TTM)
-86.94%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-166.94MUSDvs all stocks (USD)
Net Income (TTM)
-171.20MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-140.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-82.43MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2026 · Mar 31, 2026Operating Income
-142.59MUSDvs all stocks (USD)
Pre-tax Income
-148.00MUSDFY2026 · Mar 31, 2026Net Income
-148.00MUSDFY2026 · Mar 31, 2026EBIT
-142.59MUSDFY2026 · Mar 31, 2026EBITDA (Income Statement)
-137.46MUSDFY2026 · Mar 31, 2026Research & Development
86.59MUSDFY2026 · Mar 31, 2026Selling, General & Administrative
56.00MUSDFY2026 · Mar 31, 2026Non-operating Interest Income
5.10MUSDFY2026 · Mar 31, 2026Net Income from Continuing Operations
-148.00MUSDFY2026 · Mar 31, 2026Operating Cash Flow
-135.93MUSDFY2026 · Mar 31, 2026Free Cash Flow
-137.29MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
157.26MUSDFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-148.00MUSDFY2026 · Mar 31, 2026Depreciation & Amortization
120.00KUSDFY2026 · Mar 31, 2026Stock-based Compensation
10.86MUSDFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-934.00KUSDFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
2.02MUSDFY2026 · Mar 31, 2026Capital Expenditures
-1.36MUSDFY2026 · Mar 31, 2026Net Investing Cash Flow
-1.36MUSDFY2026 · Mar 31, 2026Long-term Debt Payments
-20.15MUSDFY2026 · Mar 31, 2026Net Short-term Debt Issuance
24.35MUSDFY2026 · Mar 31, 2026Other Financing Charges
-315.00KUSDFY2026 · Mar 31, 2026Net Financing Cash Flow
149.94MUSDFY2026 · Mar 31, 2026Shares Outstanding
61.98MSharesUpdated Sep 27, 2026Float Shares
58.56MSharesUpdated Sep 27, 2026Shares Short
3.02MSharesUpdated Sep 27, 2026Short Ratio
2.16daysvs all stocks
% Held by Insiders
14.03%vs all stocks
% Held by Institutions
41.26%vs all stocks
Total Cash (MRQ)
166.36MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.28USDUpdated Sep 27, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
10.97xvs Biotechnology peers
Book Value per Share (MRQ)
3.91USDUpdated Sep 27, 2026Total Assets
354.58MUSDvs all stocks (USD)
Total Current Assets
260.50MUSDFY2026 · Mar 31, 2026Total Liabilities
27.36MUSDFY2026 · Mar 31, 2026Total Non-current Assets
94.08MUSDFY2026 · Mar 31, 2026Total Non-current Liabilities
0.00USDFY2026 · Mar 31, 2026Total Current Liabilities
27.36MUSDFY2026 · Mar 31, 2026Cash
222.01MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents
222.01MUSDFY2026 · Mar 31, 2026Accounts Receivable
7.10MUSDFY2026 · Mar 31, 2026Common Stock (Book)
694.72MUSDFY2026 · Mar 31, 2026Retained Earnings
-549.92MUSDFY2026 · Mar 31, 2026Total Shareholders' Equity
327.22MUSDvs all stocks (USD)
52-Week Low
3.76USDUpdated Sep 27, 202652-Week High
15.15USDUpdated Sep 27, 202652-Week Change
110.52%vs all stocks
Beta
0.6320xvs all stocks
50-Day MA
11.09USDUpdated Sep 27, 2026200-Day MA
7.22USDUpdated Sep 27, 2026Avg 10-Day Volume
2.14MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.72MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-4.06USDUpdated Sep 27, 2026Other Income / Expense
-7.59MUSDFY2026 · Mar 31, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow